Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Mohamad Ali Toufic Najia, Deepak Kumar Jha, Cheng Zhang, Benoît Laurent, Caroline Kubaczka, Arianna Markel, Christopher Li, Vivian Morris, Allison Tompkins, Luca T. Hensch, Yue Qin, Bjoern Chapuy, Yu-Chung Huang, Michael Morse, Matthew R. Marunde, , George Q. Daley
The paper identifies KDM4 demethylase inhibition as a therapeutic strategy for lymphoma and other cancers by rewiring heterochromatin and inducing DNA damage.
bioRxiv · Jan 31, 2025 · PreprintGenomics